Imatinib prevents dexamethasone‐induced pancreatic β‐cell apoptosis via decreased TRAIL and DR5
Journal of Cellular Biochemistry · 2023
DOI: 10.1002/jcb.30450 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2023. Verfasst von Suchanoot Kutpruek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: NF-kappa B, Superoxides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Prolonged administration of dexamethasone, a potent anti‐inflammatory drug, can lead to steroid‐induced diabetes . Imatinib, a medication commonly prescribed for chronic myeloid leukemia (CML), has been shown to improve diabetes in CML patients. Our recent study demonstrated that dexamethasone induces pancreatic β‐cell apoptosis by upregulating the expression of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) and its receptor, death receptor 5 (DR5). We hypothesized that imatinib may protect against dexamethasone‐induced pancreatic β‐cell apoptosis by reducing the expression of TRAIL and DR5, thereby favorably modulating downstream effectors in apoptotic pathways. We test this hypothesis by assessing the effects of imatinib on dexamethasone‐induced apoptosis in rat insulinoma cell line cells. As anticipated, dexamethasone treatment led to increased TRAIL and DR5 expression, as well as an elevation in superoxide production. Conversely, expression of the TRAIL decoy receptor (DcR1) was decreased. Moreover, key effectors in the extrinsic and intrinsic apoptosis pathways, such as B‐cell lymphoma 2 (BCL‐2) associated X (BAX), nuclear factor kappa B (NF‐κb), P73, caspase 8, and caspase 9, were upregulated, while the antiapoptotic protein BCL‐2 was downregulated. Interestingly and importantly, imatinib at a concentration of 10 µM reversed the effect of dexamethasone on TRAIL, DR5, DcR1, superoxide production, BAX, BCL‐2, NF‐κB, P73, caspase 3, caspase 8, and caspase 9. Similar effects of imatinib on dexamethasone‐induced TRAIL and DR5 expression were also observed in isolated mouse islets. Taken together, our findings suggest that imatinib protects against dexamethasone‐induced pancreatic β‐cell apoptosis by reducing TRAIL and DR5 expression and modulating downstream effectors in the extrinsic and intrinsic apoptosis pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Research Department, Division of Molecular Medicine, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Suwattanee Kooptiwut
Zitieren
APA
Kutpruek, S., Suksri, K., Maneethorn, P., Semprasert, N., Yenchitsomanus, P. T., & Kooptiwut, S. (2023). Imatinib prevents dexamethasone‐induced pancreatic β‐cell apoptosis via decreased TRAIL and DR5. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.30450
Vancouver
Kutpruek S, Suksri K, Maneethorn P, Semprasert N, Yenchitsomanus PT, Kooptiwut S. Imatinib prevents dexamethasone‐induced pancreatic β‐cell apoptosis via decreased TRAIL and DR5. Journal of Cellular Biochemistry. 2023. doi:10.1002/jcb.30450
BibTeX
@article{Kutpruek2023,
author = {Kutpruek, Suchanoot and Suksri, Kanchana and Maneethorn, Petcharee and Semprasert, Namoiy and Yenchitsomanus, Pa-Thai and Kooptiwut, Suwattanee},
title = {Imatinib prevents dexamethasone‐induced pancreatic β‐cell apoptosis via decreased TRAIL and DR5},
journal = {Journal of Cellular Biochemistry},
year = {2023},
doi = {10.1002/jcb.30450}
}
EUVIMED